Alnylam Pharmaceuticals | ALNY - Debt



Alnylam Pharmaceuticals reported $1.3B in Debt for its fiscal quarter ending in June of 2025.


Debt Change Date
Acadia Pharmaceuticals USD 56.29M 56.29M Jun/2025
Agios Pharmaceuticals USD 48.76M 48.76M Jun/2025
Alnylam Pharmaceuticals USD 1.3B 271.5M Jun/2025
Amgen USD 56.2B 1.18B Jun/2025
Arrowhead Research USD 388.24M 21.18M Mar/2025
BioMarin Pharmaceutical USD 603.87M 8.22M Jun/2025
Incyte USD 42.41M 5.29M Jun/2025
Ionis Pharmaceuticals USD 1.42B 169.27M Jun/2025
Moderna USD 741M 4M Jun/2025
Neurocrine Biosciences USD 439.1M 8.4M Jun/2025
Novartis USD 32.64B 1.38B Jun/2025
PTC Therapeutics USD 286.01M 2.12B Jun/2025
Regeneron Pharmaceuticals USD 2.71B 300K Jun/2025
Sanofi 22.28B 4.38B Jun/2025
Sarepta Therapeutics USD 1.35B 215.59M Jun/2025
Takeda JPY 4.51T 9.32B Jun/2025
Tectonic Therapeutic USD 876K 115K Dec/2024
Ultragenyx Pharmaceutical USD 36.3M 1.98M Jun/2025
Vertex Pharmaceuticals USD 1.53B 121.7M Jun/2025
Xencor USD 67.93M 86.45M Jun/2025